CN108350059B - 识别hla-cw8限制性突变kras的t细胞受体 - Google Patents

识别hla-cw8限制性突变kras的t细胞受体 Download PDF

Info

Publication number
CN108350059B
CN108350059B CN201680058891.3A CN201680058891A CN108350059B CN 108350059 B CN108350059 B CN 108350059B CN 201680058891 A CN201680058891 A CN 201680058891A CN 108350059 B CN108350059 B CN 108350059B
Authority
CN
China
Prior art keywords
seq
leu
val
amino acid
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680058891.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN108350059A (zh
Inventor
埃里克·特兰
卢勇成
史蒂文·A·罗森伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of Health and Human Services
Original Assignee
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of Health and Human Services filed Critical United States Department of Health and Human Services
Priority to CN202111083392.9A priority Critical patent/CN115073583A/zh
Publication of CN108350059A publication Critical patent/CN108350059A/zh
Application granted granted Critical
Publication of CN108350059B publication Critical patent/CN108350059B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
CN201680058891.3A 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体 Active CN108350059B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111083392.9A CN115073583A (zh) 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562218688P 2015-09-15 2015-09-15
US62/218,688 2015-09-15
PCT/US2016/050875 WO2017048593A1 (en) 2015-09-15 2016-09-09 T cell receptors recognizing hla-cw8 restricted mutated kras

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202111083392.9A Division CN115073583A (zh) 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体

Publications (2)

Publication Number Publication Date
CN108350059A CN108350059A (zh) 2018-07-31
CN108350059B true CN108350059B (zh) 2021-10-08

Family

ID=56985686

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680058891.3A Active CN108350059B (zh) 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体
CN202111083392.9A Pending CN115073583A (zh) 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202111083392.9A Pending CN115073583A (zh) 2015-09-15 2016-09-09 识别hla-cw8限制性突变kras的t细胞受体

Country Status (13)

Country Link
US (3) US10556940B2 (cg-RX-API-DMAC10.html)
EP (2) EP3901169B1 (cg-RX-API-DMAC10.html)
JP (2) JP7185524B2 (cg-RX-API-DMAC10.html)
KR (2) KR20250117744A (cg-RX-API-DMAC10.html)
CN (2) CN108350059B (cg-RX-API-DMAC10.html)
AU (3) AU2016323017B2 (cg-RX-API-DMAC10.html)
DK (1) DK3350213T3 (cg-RX-API-DMAC10.html)
ES (1) ES2879287T3 (cg-RX-API-DMAC10.html)
IL (1) IL257840B2 (cg-RX-API-DMAC10.html)
MX (1) MX2018003062A (cg-RX-API-DMAC10.html)
SA (1) SA518391109B1 (cg-RX-API-DMAC10.html)
SG (1) SG10201913868XA (cg-RX-API-DMAC10.html)
WO (1) WO2017048593A1 (cg-RX-API-DMAC10.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4339287A3 (en) 2015-07-31 2024-05-22 Regents Of The University Of Minnesota Modified cells and methods of therapy
SG11201900654QA (en) * 2016-08-02 2019-02-27 Us Health Anti-kras-g12d t cell receptors
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
EP3602053B1 (en) * 2017-03-31 2023-06-28 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of isolating neoantigen-specific t cell receptor sequences
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
CN111511375A (zh) 2017-06-30 2020-08-07 因提玛生物科学公司 用于基因治疗的腺相关病毒载体
AU2018335274B2 (en) * 2017-09-20 2025-02-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II–restricted T cell receptors against mutated RAS
US12227554B2 (en) 2017-10-05 2025-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for selectively expanding cells expressing a TCR with a murine constant region
MX2020005765A (es) 2017-12-04 2020-09-25 Us Health Receptores de celulas t restringidos a antigeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado.
SG11202012653XA (en) * 2018-06-19 2021-01-28 Biontech Us Inc Neoantigens and uses thereof
AU2019321608B2 (en) 2018-08-16 2024-07-25 Biontech Us Inc. T cell receptor constructs and uses thereof
WO2020154275A1 (en) * 2019-01-22 2020-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted t cell receptors against ras with g12r mutation
GB2613715B (en) 2019-02-20 2023-12-06 Fred Hutchinson Cancer Center Binding proteins specific for RAS neoantigens and uses thereof
US20220175899A1 (en) * 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
EP4016437A4 (en) * 2019-08-14 2022-08-17 NEC Corporation INFORMATION PROCESSING DEVICE, INFORMATION PROCESSING METHOD AND RECORDING MEDIUM
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
WO2021127184A1 (en) 2019-12-17 2021-06-24 The Johns Hopkins University MANAbodies TARGETING TUMOR ANTIGENS AND METHODS OF USING
JP2023507432A (ja) 2019-12-20 2023-02-22 インスティル バイオ （ユーケイ） リミテッド 腫瘍浸潤リンパ球を単離するためのデバイスおよび方法ならびにそれらの使用
MX2022009825A (es) * 2020-02-14 2022-10-13 Us Health Receptores de células t restringidas por hla de la clase i contra ras con mutación g12v.
US20230159614A1 (en) * 2020-02-26 2023-05-25 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class ii-restricted t cell receptors against ras with g12v mutation
CN111574616B (zh) * 2020-06-17 2021-02-02 深圳豪石生物科技有限公司 分离的t细胞受体和应用
WO2022015922A1 (en) * 2020-07-16 2022-01-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted drb t cell receptors against ras with g12v mutation
AU2021351710A1 (en) * 2020-10-02 2023-06-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103249430A (zh) * 2010-09-20 2013-08-14 生物技术公司 抗原特异性t细胞受体和t细胞表位
CN103974974A (zh) * 2011-09-15 2014-08-06 美国卫生和人力服务部 识别hla-a1-或hla-cw7-限制的mage的t细胞受体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301017B2 (en) * 2002-05-30 2007-11-27 Kolesnick Richard N Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
HUE038833T2 (hu) * 2005-08-05 2018-11-28 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Antigénspecifikus T-sejtek létrehozása
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
SG10201913978RA (en) * 2014-11-26 2020-03-30 The United States Of America As Represented By The Secretary Anti-mutated kras t cell receptors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103249430A (zh) * 2010-09-20 2013-08-14 生物技术公司 抗原特异性t细胞受体和t细胞表位
CN103974974A (zh) * 2011-09-15 2014-08-06 美国卫生和人力服务部 识别hla-a1-或hla-cw7-限制的mage的t细胞受体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif;Frederick D. Tsai等;《PNAS》;20150120;第112卷(第3期);第779–784页 *

Also Published As

Publication number Publication date
KR20180044428A (ko) 2018-05-02
US20200148739A1 (en) 2020-05-14
JP7185524B2 (ja) 2022-12-07
CN108350059A (zh) 2018-07-31
EP3350213A1 (en) 2018-07-25
JP2023025108A (ja) 2023-02-21
SG10201913868XA (en) 2020-03-30
US20190040111A1 (en) 2019-02-07
AU2022209229A1 (en) 2022-09-15
US12673981B2 (en) 2026-07-07
WO2017048593A1 (en) 2017-03-23
AU2021200833B2 (en) 2022-04-28
EP3901169B1 (en) 2026-01-28
AU2016323017B2 (en) 2020-11-12
ES2879287T3 (es) 2021-11-22
HK1257902A1 (en) 2019-11-01
KR102841067B1 (ko) 2025-08-01
IL257840B1 (en) 2023-06-01
JP7461445B2 (ja) 2024-04-03
IL257840B2 (en) 2023-10-01
KR20250117744A (ko) 2025-08-05
MX2018003062A (es) 2018-09-11
US20230406904A1 (en) 2023-12-21
CA2998869A1 (en) 2017-03-23
IL257840A (en) 2018-04-30
US11667692B2 (en) 2023-06-06
EP3901169A1 (en) 2021-10-27
DK3350213T3 (da) 2021-06-21
AU2021200833A1 (en) 2021-03-04
EP3350213B1 (en) 2021-03-31
SA518391109B1 (ar) 2022-02-14
AU2016323017A1 (en) 2018-04-05
JP2018535647A (ja) 2018-12-06
CN115073583A (zh) 2022-09-20
US10556940B2 (en) 2020-02-11
AU2022209229B2 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
US20230406904A1 (en) T cell receptors recognizing hla-cw8 restricted mutated kras
KR102527052B1 (ko) 항-kras-g12d t 세포 수용체
AU2017258745B2 (en) Anti-KK-LC-1 T cell receptors
JP7635165B2 (ja) ｐ５３におけるＲ１７５Ｈ又はＹ２２０Ｃ変異を認識するＴ細胞受容体
US20230159614A1 (en) Hla class ii-restricted t cell receptors against ras with g12v mutation
EP4612170A1 (en) T cell receptors targeting mutated cdkn2a
KR20230046294A (ko) G12v 돌연변이를 갖는 ras에 대한 hla 클래스 ii-제한된 drb t 세포 수용체
CA2998869C (en) T cell receptors recognizing hla-cw8 restricted mutated kras
RU2830061C2 (ru) T-клеточные рецепторы, распознающие мутацию r175h или y220c в p53
US20230312672A1 (en) Hla class i-restricted t cell receptors against cd20
WO2022225836A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation
HK1257902B (en) T cell receptors recognizing hla-cw8 restricted mutated kras
EP4612169A1 (en) Hla-a3-restricted t cell receptors against braf with v600e mutation
WO2022177961A1 (en) Hla class i–restricted t cell receptors against cd22
EA045621B1 (ru) T-клеточные рецепторы, рестриктированные по антигену лейкоцитов человека класса ii, против мутантного ras

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant